Sionna Therapeutics, Inc. cash flow to debt ratio of -764.05% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sionna Therapeutics, Inc.'s free cash flow has decreased 26.24% from $-52.81M last year to $-66.67M, signaling decreasing performance

Sionna Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Sionna Therapeutics, Inc.'s debt has increased relative to shareholder equity from -0.06 last year to 0.03 today, signaling weakened financials

Sionna Therapeutics, Inc. has a net cash position, so leverage is healthy.

Sionna Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Sionna Therapeutics, Inc. has insufficient data to evaluate this check.

Sionna Therapeutics, Inc.'s short-term assets of $241.42M exceed its short-term liabilities of $11.71M

Sionna Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sionna Therapeutics, Inc.'s return on equity of -32.94%, is lower than 15.00%, indicating bad performance

Sionna Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sionna Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Sionna Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sionna Therapeutics, Inc. has negative free cash flow, indicating cash burn

Sionna Therapeutics, Inc.'s yearly earnings has decreased 22.01% since last year from $-61.69M to $-75.27M, signaling decreasing performance

Sionna Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -40.18% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sionna Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Sionna Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Sionna Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Sionna Therapeutics, Inc. has insufficient data to evaluate this check.

Sionna Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sionna Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sionna Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sionna Therapeutics, Inc. has insufficient data to evaluate this check.

Sionna Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sionna Therapeutics, Inc. has a price-to-book ratio of 0.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sionna Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue